DLOC Biosystems

What DLOC Biosystems does

DLOC Biosystems is a biotechnology company developing organ-on-chip technology for pre-clinical drug testing, spun off from the Mechanical Engineering department at the American University of Beirut (AUB) and now headquartered at Discovery Park in Sandwich, Kent, UK. The company's core product platform is built around three components: the patented Duct Organ-On-Chip (DOOC) device, a porous ductal scaffold that grows 3D human tissue in-vitro while preserving in-vivo tissue properties such as cell polarity and cell-ECM interaction; the patented Human-On-Chip Operating System (HOS), an automated device comprising a Human-on-chip plate for multiplexed micro-valving and micro-channeling across multiple tissue types, plus a controller that manages fluid flow and real-time tissue functionality measurements via microscopy, spectroscopy, and FTIR; and an AI-Powered Drug Testing (AI-HOS) module that layers predictive analytics on top of the HOS platform to forecast drug success and failure prior to clinical trials.

The company targets pharmaceutical and biotechnology companies developing new drugs and biologics, with a secondary segment of contract research organizations (CROs) that provide outsourced pre-clinical testing services. Its go-to-market motion is sales-led and B2B, focused on direct enterprise engagement with drug development teams. The stated business model combines pre-clinical on-chip testing services (professional services revenue) with technology licensing of the patented DOOC and HOS devices (licensing and royalties). Pricing is not publicly disclosed and is handled through contact-based quoting.

DLOC has built its early capitalization through non-dilutive funding, winning multiple regional and international entrepreneurship competitions (Stars-of-Science, Arab Entrepreneurship Rally, LIRA Forum, MIT Enterprise Forum, Darwazah Student Entrepreneurship Contest) and grants from organizations including the Kuwait Chamber of Commerce. The company currently operates with a team of 21 people focused on technology innovation, customer and partnership acquisition, and ongoing fundraising. No institutional venture funding rounds, named customers, ARR, or revenue figures have been disclosed.

Name

DLOC Biosystems

Legal name

DLOC Biosystems

Website

https://dlocbiosystems.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

DLOC Biosystems is a biotechnology company developing patented organ-on-chip technology, including the Duct Organ-On-Chip device and Human-On-Chip Operating System with an AI-Powered Drug Testing module, for pre-clinical drug testing services to pharmaceutical and biotechnology companies.

Ownership category

akta.pro rank

Product category

Organ-on-Chip Technology / Pre-Clinical Drug Testing Equipment

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Analytical Laboratory Instrument Manufacturing (334516)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)

akta.pro primary industry

In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems) (HLAAAIAJ)

akta.pro secondary industries

Organoids & Organ-on-Chip (regenerative models) (HLAAAGAD), AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), Cellomics & High-Content Screening (HCS) Services (HLAGANAD)

Keywords

• Organ-on-chip technology
• Drug discovery platforms
• Pre-clinical testing services
• Tissue engineering devices
• Micro-physiological systems

Headquarters

HQ city

Aley

HQ country

Lebanon

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Pre-clinical Trial On-Chip Testing Services: DLOC aims to offer pre-clinical trials on-chip testing service that would significantly reduce the cost of drug development and increase trial safety. This service-based model allows pharmaceutical companies to test drug candidates on human models prior to clinical trials.
2. Technology Licensing: The company has developed and patented its organ-on-chip technology and automated HOS device. Licensing of this technology to pharmaceutical and biotech companies represents a potential revenue stream.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

DLOC Biosystems develops, manufactures, and has patented organ-on-chip devices and an automated multi-organ operating system used for pre-clinical drug testing. The company's product portfolio includes the Duct Organ-On-Chip (DOOC), the Human-On-Chip Operating System (HOS), and the AI-Powered Drug Testing (AI-HOS) platform, enabling pharmaceutical and biotech companies to test drug candidates on human tissue models prior to clinical trials.

Product overview

DLOC Biosystems offers a multi-product platform centered on organ-on-chip technology for drug discovery. The core offering is the Duct Organ-On-Chip (DOOC), a patented device for growing 3D human tissue in-vitro while preserving in-vivo properties. This integrates with the Human-On-Chip Operating System (HOS), which consists of the Human-on-chip plate (HOC) for multi-organ modeling and the HOS controller for fluid management and real-time measurements. The AI-Powered Drug Testing (AI-HOS) module adds AI capabilities on top of the HOS platform for enhanced drug testing and prediction. Together, these products enable pre-clinical on-chip drug testing that reduces development costs and increases trial safety.

Differentiator

Problem solved

Functional benefit

Brands

• Duct Organ-On-Chip (DOOC): A revolutionary organ-on-chip device with a porous ductal scaffold that preserves 3D structure and tissue microenvironment, allowing for growing 3D human tissue in-vitro while preserving in-vivo tissue properties.
• Human-On-Chip Operating System (HOS)
• AI-Powered Drug Testing (AI-HOS)

Products and services

• Duct Organ-On-Chip (DOOC) A patented organ-on-chip device featuring a porous ductal scaffold that preserves 3D structure and tissue microenvironment, allowing growth of 3D human tissue in-vitro while maintaining in-vivo tissue properties including cell-cell interaction (cell polarity) and cell-tissue interaction (ECM). Targeted at pharmaceutical and biotech companies for pre-clinical drug testing.
• Human-On-Chip Operating System (HOS) A patented automated machine that models the human body's circulatory, immune, and hormonal systems across multi-organ models. Consists of two components: the Human-on-chip plate (HOC) for multiplexed micro-valving and micro-channeling of multiple connected chips, and the HOS controller that manages fluid flow, samples small volumes from different culture regions, and measures real-time tissue functionality using microscopy, spectroscopy, and FTIR. Targeted at pharmaceutical and biotech companies for pre-clinical drug testing.
• AI-Powered Drug Testing (AI-HOS) An AI-powered drug testing system integrated with the Human-on-chip Operating System that leverages machine learning for drug discovery applications. Enables accurate prediction of drug success and failure prior to clinical trials by analyzing results from the HOS platform's tissue models.
• Pre-clinical On-Chip Testing Service A pre-clinical drug testing service offered to pharmaceutical and biotech companies that enables drug candidates to be tested on human tissue models using DLOC's organ-on-chip platform prior to clinical trials. Aimed at significantly reducing drug development costs and increasing trial safety.

Quantifiable outcome

• 90% drug candidate failure rate at clinical trials could be reduced through accurate pre-clinical prediction using human-on-chip models

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• American University of Beirut (AUB) - Mechanical Engineering DepartmentcoreStrategic or Co-development PartnerDLOC Biosystems spun off from the mechanical engineering department at AUB. The technology originated from a research project studying breast cancer metastasis in mammary ducts. The company was initially incubated at the AUB Darwazah Center, which provided early support and resources for technology development.

Scale indicators2 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• InSphero AG: Swiss-based 3D microtissue and organoid company offering Akura plate technology and pre-clinical assay services. Comparable to DLOC as it provides 3D tissue-based pre-clinical drug testing services and devices to pharma/biotech.
• CN Bio Innovations: UK-based organ-on-chip company with its PhysioMimix platform for single- and multi-organ microphysiological systems. Direct competitor to DLOC given overlapping geography (UK life sciences market) and similar pharma-services plus device business model.
• TissUse GmbH: Berlin-based organ-on-chip company developing multi-organ-chip (MOC) systems that connect multiple organ models on a chip. Directly comparable to DLOC's HOS multi-organ approach and sells pre-clinical testing services to pharma and cosmetics companies.
• Nortis (acquired by BICO): Organ-on-chip platform now part of BICO Group, developing microfluidic chip systems for pre-clinical testing. Direct peer in the OoC device-and-services space with comparable target customers and applications.
• Hesperos, Inc. US-based human-on-chip company developing multi-organ systems without pumps for serum-free disease modeling. Directly comparable to DLOC's human-on-chip positioning and pre-clinical testing service offering.
• Emulate, Inc. US-based organ-on-chip company and the most commercially advanced player in the category. Directly comparable to DLOC as it sells organ-on-chip platforms and pre-clinical testing services to pharma; it has established multi-year pharma collaborations and is the benchmark competitor DLOC must differentiate against.
• MIMETAS: Netherlands-based organ-on-chip company offering the OrganoPlate platform for 3D tissue models and high-throughput screening. Comparable to DLOC as it sells organ-on-chip devices and assay services to pharma/biotech drug discovery teams.

Emerging players

• Quris Technologies: Israel-based AI-on-chip drug safety platform using organ-on-chip technology with machine-learning prediction. Comparable to DLOC's AI-HOS angle and emerging as a competitive AI-augmented OoC testing player.
• AxoSim, Inc. US-based nerve-on-chip and organoid platform for pre-clinical testing in neuroscience. Comparable to DLOC as an emerging organ-on-chip services company targeting pharma R&D, though narrower in organ scope.

Broad incumbents

• Organovo Holdings: Public 3D bioprinted tissue company with broader tissue-engineering scope. Less directly competitive on organ-on-chip devices, but a comparable incumbent in the 3D tissue/pre-clinical testing market DLOC addresses.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/dloc-biosystems

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DLOC Biosystems